DEF 14A: 60 Degrees Pharma Seeks Reverse Split, Boosts Equity Plan

60 Degrees Pharmaceuticals, Inc. will hold its 2025 Annual Meeting to vote on a reverse stock split, an increase in its equity incentive plan shares, and director elections, aiming to maintain Nasdaq listing and attract talent.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on October 8, 2025, at 12:00 p.m. Eastern Time.
• Stockholders will vote on the election of five directors to serve until the 2026 Annual Meeting.
• A proposal seeks to amend the 2022 Equity Incentive Plan to increase the number of shares available for issuance by 250,000, bringing the total to 465,452 shares.
• An amendment to the Certificate of Incorporation is proposed to effect a reverse stock split at a ratio ranging from 1:3 to 1:10, at the Board's discretion, primarily to maintain Nasdaq listing.
• Stockholders will also ratify the selection of RBSM LLP as the independent auditor for the fiscal year ending December 31, 2025.
• A proposal to approve adjourning the Annual Meeting, if necessary, to solicit additional proxies for the director election, equity plan amendment, and reverse stock split proposals will also be voted on.
• As of the Record Date, August 26, 2025, there were 4,104,469 shares of common stock outstanding.

Sentiment

Score: 4

Explanation: The company is proactively addressing critical issues like Nasdaq listing compliance and employee incentives, which are necessary for its continued operation. However, the underlying need for a reverse stock split due to a low stock price and the disclosed delinquent SEC filings for key personnel are significant negative indicators, suggesting operational or compliance challenges.

Positives

• The Board of Directors unanimously recommends voting FOR all proposed actions, indicating internal alignment on strategic initiatives.
• Increasing the shares available under the 2022 Equity Incentive Plan aims to attract and retain highly motivated and qualified employees in a competitive labor market.
• The proposed reverse stock split is a proactive measure to maintain the company's listing on The Nasdaq Capital Market, which is crucial for market access and investor confidence.
• The company has established corporate governance practices, including independent directors and active committees (Audit, Compensation, Nominating and Corporate Governance).

Negatives

• The necessity of a reverse stock split indicates a low per-share trading price, which could reflect underlying performance challenges or market perception issues.
• A reverse stock split may not proportionally increase the stock price, potentially leading to a reduction in overall market capitalization and decreased liquidity.
• Two directors/executive officers, Cheryl Xu and Kristen Landon, failed to file timely Section 16(a) reports, raising concerns about internal compliance and governance oversight.
• The increase in authorized shares, while providing flexibility, could lead to future dilution for existing shareholders if new shares are issued without corresponding value creation.

Risks

• The effect of a reverse stock split on the stock price cannot be predicted with certainty, and the price may not increase proportionally, potentially reducing overall market capitalization.
• A reverse stock split may decrease the liquidity of common stock and result in higher transaction costs, particularly for stockholders owning odd lots.
• An effective increase in authorized shares due to a reverse stock split could have anti-takeover implications, potentially deterring or preventing changes in control.
• Failure to meet Nasdaq's continued listing requirements could lead to suspension of trading and delisting, adversely affecting financing, trading, and stock value.

Future Outlook

The company aims to maintain its Nasdaq listing by implementing a reverse stock split, which is intended to raise the per-share trading price. It also seeks to enhance its ability to attract and retain key talent through an expanded equity incentive plan. The additional authorized shares from the reverse split are intended to provide flexibility for future capital raises, debt repurchases, equity incentives, and business expansion, though no specific plans are currently in place.

Management Comments

• "On behalf of your Board of Directors, we cordially invite you to attend the 2025 Annual Meeting of Stockholders of 60 Degrees Pharmaceuticals, Inc." Geoffrey Dow, CEO and President.
• "We are pleased to furnish proxy materials to stockholders primarily over the internet. We believe that this process expedites stockholders receipt of proxy materials, lowers the costs of our Annual Meeting and conserves natural resources." Geoffrey Dow, CEO and President.
• "After careful consideration, the Board has determined that each proposal listed above is in the best interests of the Company and its stockholders and has approved each proposal. The Board recommends a vote FOR the Election of each director nominee (Proposal 1), FOR the approval of an amendment to the 2022 Plan (Proposal 2), FOR the approval of an amendment to our Certificate of Incorporation (Proposal 3), FOR the ratification of our independent auditor (Proposal 4) and FOR the approval of the Adjournment Proposal (Proposal 5)."

Industry Context

The company operates in an industry with a competitive labor market, necessitating robust equity compensation plans to attract and retain skilled personnel. Maintaining a Nasdaq listing is critical for visibility and access to capital within the pharmaceutical and biotechnology sectors.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will vote on significant corporate actions, including a reverse stock split and equity plan expansion, which could impact their ownership percentage, stock price, and potential for future dilution.
• Employees: The expanded equity incentive plan aims to provide additional incentives and improve retention, directly benefiting employees eligible for awards.
• Management: Executive compensation adjustments and new option grants are detailed, reflecting the Board's decisions on leadership incentives.
• Regulatory Bodies: The company is addressing Nasdaq listing compliance, and the disclosure of delinquent Section 16(a) reports highlights areas for potential regulatory attention.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on October 8, 2025.
• If approved, the Board will determine whether and when to effectuate the reverse stock split within one year of the meeting.
• The company will announce the final voting results on a Current Report on Form 8-K filed with the SEC within four business days after the Annual Meeting.
• Management will report on the company's performance and respond to stockholder questions after the Annual Meeting.

Key Dates

Recommendation

A 'hold' recommendation is appropriate given the company's proactive steps to address critical issues, such as maintaining its Nasdaq listing through a proposed reverse stock split and enhancing employee incentives via an expanded equity plan. These actions are necessary for the company's long-term viability and growth. However, the underlying need for a reverse stock split indicates a low stock price, and the disclosed delinquent Section 16(a) reports for key personnel raise concerns about internal controls and compliance. Investors should monitor the outcome of these proposals and the company's ability to execute its strategy and improve compliance before making further investment decisions.

Keywords

60 Degrees Pharmaceuticals, SXTP, Proxy Statement, Annual Meeting, Reverse Stock Split, Equity Incentive Plan, Nasdaq Listing, Corporate Governance, Biotech, Pharmaceuticals, Stockholder Vote